Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitchell R Smith

Showing results (11-20 of 129) with videos related to

Pageof 13
Sort By:
Current Treatment Options in Oncology|August 22, 2016
Antibody Drug Conjugates (ADCs): Changing the Treatment Landscape of LymphomaDeepa Jagadeesh, Mitchell R Smith
Leukemia Research|May 23, 2018
Optimal use of novel agents in chronic lymphocytic leukemiaMitchell R Smith, Robert F Weiss
Best Practice & Research. Clinical Haematology|June 13, 2012
Radioimmunotherapy in mantle cell lymphomaAlan P Skarbnik, Mitchell R Smith
Discovery Medicine|April 3, 2013
Therapies for mantle cell lymphoma: current challenges and a brighter futureAlan P Skarbnik, Mitchell R Smith
Expert Opinion on Biological Therapy|March 28, 2012
Brentuximab vedotin in anaplastic large cell lymphomaAlan P Z Skarbnik, Mitchell R Smith
P & T : a Peer-Reviewed Journal for Formulary Management|May 6, 2010
Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's LymphomaEfrat Dotan, Charu Aggarwal, Mitchell R Smith
Molecular Cancer Therapeutics|January 7, 2005
Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenograftsMitchell R Smith, Fang Jin, Indira Joshi
British Journal of Haematology|January 7, 2014
Milatuzumab and veltuzumab induce apoptosis through JNK signalling in an NF-κB dependent human transformed follicular lymphoma cell lineMitchell R Smith, Fang Jin, Indira Joshi
Oman Journal of Ophthalmology|May 5, 2012
Lacrimal gland lymphoma: Role of radiation therapyNatasha Townsend, Aruna Turaka, Mitchell R Smith
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2007
Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2Mitchell R Smith, Fang Jin, Indira Joshi
Pageof 13

Showing results (11-20 of 129) with videos related to

Sort By:
Pageof 13
Current Treatment Options in Oncology|August 22, 2016
Antibody Drug Conjugates (ADCs): Changing the Treatment Landscape of LymphomaDeepa Jagadeesh, Mitchell R Smith
Leukemia Research|May 23, 2018
Optimal use of novel agents in chronic lymphocytic leukemiaMitchell R Smith, Robert F Weiss
Best Practice & Research. Clinical Haematology|June 13, 2012
Radioimmunotherapy in mantle cell lymphomaAlan P Skarbnik, Mitchell R Smith
Discovery Medicine|April 3, 2013
Therapies for mantle cell lymphoma: current challenges and a brighter futureAlan P Skarbnik, Mitchell R Smith
Expert Opinion on Biological Therapy|March 28, 2012
Brentuximab vedotin in anaplastic large cell lymphomaAlan P Z Skarbnik, Mitchell R Smith
P & T : a Peer-Reviewed Journal for Formulary Management|May 6, 2010
Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's LymphomaEfrat Dotan, Charu Aggarwal, Mitchell R Smith
Molecular Cancer Therapeutics|January 7, 2005
Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenograftsMitchell R Smith, Fang Jin, Indira Joshi
British Journal of Haematology|January 7, 2014
Milatuzumab and veltuzumab induce apoptosis through JNK signalling in an NF-κB dependent human transformed follicular lymphoma cell lineMitchell R Smith, Fang Jin, Indira Joshi
Oman Journal of Ophthalmology|May 5, 2012
Lacrimal gland lymphoma: Role of radiation therapyNatasha Townsend, Aruna Turaka, Mitchell R Smith
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2007
Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2Mitchell R Smith, Fang Jin, Indira Joshi
Pageof 13